AAAAAA
Results: 1-25/32
Authors:
Kern, W
Schleyer, E
Braess, J
Wittmer, E
Ohnesorge, J
Unterhalt, M
Wormann, B
Buchner, T
Hiddemann, W
Citation: W. Kern et al., Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone [FIS-HAM] salvage therapy in highly resistant acuteleukemias, ANN HEMATOL, 80(6), 2001, pp. 334-339
Authors:
Yilmaz, A
Kaufmann, CC
Binder, C
Wormann, B
Haase, D
Citation: A. Yilmaz et al., Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome, ANN HEMATOL, 80(1), 2001, pp. 53-57
Authors:
Jahns-Streubel, G
Braess, J
Schoch, C
Fonatsch, C
Haase, D
Binder, C
Wormann, B
Buchner, T
Hiddemann, W
Citation: G. Jahns-streubel et al., Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF, LEUKEMIA, 15(3), 2001, pp. 377-384
Authors:
Buchner, T
Hiddemann, W
Berdel, W
Wormann, B
Loffler, H
Schoch, C
Haferlach, T
Ludwig, WD
Maschmeyer, G
Staib, P
Andreesen, R
Balleisen, L
Haase, D
Eimermacher, H
Aul, C
Rasche, H
Uhlig, J
Gruneisen, A
Reis, HE
Hartlapp, J
Hirschmann, WD
Weh, HJ
Pielken, HJ
Gassmann, W
Sauerland, MC
Heinecke, A
Citation: T. Buchner et al., Remission induction therapy: the more intensive the better?, CANC CHEMOT, 48, 2001, pp. S41-S44
Authors:
Behr, TM
Behe, M
Wormann, B
Citation: Tm. Behr et al., Trastuzumab and breast cancer., N ENG J MED, 345(13), 2001, pp. 995-996
Authors:
Schnittger, S
Kinkelin, U
Schoch, C
Haase, D
Haferlach, T
Buchner, T
Wormann, B
Hiddemann, W
Griesinger, F
Citation: S. Schnittger et al., MLL-duplications are rare and associated with poor prognosis in acute myeloid leukemia, HEMAT BLOOD, 40, 2001, pp. 27-33
Authors:
Beyer-Sehlmeyer, G
Kneba, M
Hiddemann, W
Wormann, B
Bertram, J
Citation: G. Beyer-sehlmeyer et al., Analysis of the apoptotic signal transduction cascade and new differentially expressed genes in drug resistant and sensitive hematopoetic cell lines, HEMAT BLOOD, 40, 2001, pp. 136-145
Authors:
Kern, W
Matylis, A
Gruneisen, T
Huber, C
Grote-Metke, A
Wormann, B
Buchner, T
Ohnesorge, J
Ludwig, WD
Hiddemann, W
Citation: W. Kern et al., Modulation of AraC by fludarabine: Results of salvage therapy by AMLCG, HEMAT BLOOD, 40, 2001, pp. 201-209
Authors:
Kern, W
Schoch, C
Haferlach, T
Braess, J
Unterhalt, M
Wormann, B
Buchner, T
Hiddemann, W
Citation: W. Kern et al., Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Significance of cytogenetic abnormalities, HEMAT BLOOD, 40, 2001, pp. 330-338
Authors:
Kern, W
Matylis, A
Gruneisen, T
Huber, C
Grote-Metke, A
Wormann, B
Buchner, T
Ohnesorge, J
Ludwig, WD
Hiddemann, W
Citation: W. Kern et al., Randomized comparison of sequential high-dose cytosine arabinoside and idarubicin (S-HAI) with or without chemo-modulation by fludarabine in refractory and relapsed acute myeloid leukemia, HEMAT BLOOD, 40, 2001, pp. 578-587
Authors:
Buchner, T
Hiddemann, W
Wormann, B
Loffler, H
Ludwig, WD
Schoch, C
Haferlach, T
Maschmeyer, G
Staib, P
Aul, C
Heyll, A
Gruneisen, A
Rasche, H
Eimermacher, H
Balleisen, L
Pielken, HJ
Reis, HE
Griesinger, F
Reichle, A
Sauerland, MC
Heinecke, A
Citation: T. Buchner et al., Acute myeloid leukemia in adults: Is postconsolidation maintenance therapynecessary?, INT J HEMAT, 72(3), 2000, pp. 285-289
Authors:
Lengfelder, E
Reichert, A
Schoch, C
Haase, D
Haferlach, T
Loffler, H
Staib, P
Heyll, A
Seifarth, W
Saussele, S
Fonatsch, C
Gassmann, W
Ludwig, WD
Hochhaus, A
Beelen, D
Aul, C
Sauerland, MC
Heinecke, A
Hehlmann, R
Wormann, B
Hiddemann, W
Buchner, T
Citation: E. Lengfelder et al., Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia, LEUKEMIA, 14(8), 2000, pp. 1362-1370
Authors:
Schnittger, S
Kinkelin, U
Schoch, C
Heinecke, A
Haase, D
Haferlach, T
Buchner, T
Wormann, B
Hiddemann, W
Griesinger, F
Citation: S. Schnittger et al., Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML, LEUKEMIA, 14(5), 2000, pp. 796-804
Authors:
Kern, W
Schoch, C
Haferlach, T
Braess, J
Unterhalt, M
Wormann, B
Buchner, T
Hiddemann, W
Citation: W. Kern et al., Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities, LEUKEMIA, 14(2), 2000, pp. 226-231
Authors:
Kern, W
Schoch, C
Fonatsch, C
Heinecke, A
Wormann, B
Buchner, T
Hiddemann, W
Citation: W. Kern et al., Treatment of acute myeloid leukaemia in elderly patients, DEUT MED WO, 124(34-35), 1999, pp. 1005-1014
Authors:
Liersch, T
Siggelkow, H
Hufner, M
Wormann, B
Becker, H
Wulf, GG
Citation: T. Liersch et al., Parathyroid hormone-related protein (PTHrP) in breast cancer: An auto-/paracrine growth factor? Studies on cells of the bone marrow microenvironment, LANG ARCH S, 1999, pp. 711-715
Authors:
Behr, TM
Salib, AL
Liersch, T
Behe, M
Angerstein, C
Blumenthal, RD
Fayyazi, A
Sharkey, RM
Ringe, B
Becker, H
Wormann, B
Hiddemann, W
Goldenberg, DM
Becker, W
Citation: Tm. Behr et al., Radioimmunotherapy of small volume disease of colorectal cancer metastaticto the liver: Preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study, CLIN CANC R, 5(10), 1999, pp. 3232S-3242S
Authors:
Behr, TM
Wormann, B
Gramatzki, M
Riggert, J
Gratz, S
Behe, M
Griesinger, F
Sharkey, RM
Kolb, HJ
Hiddemann, W
Goldenberg, DM
Becker, W
Citation: Tm. Behr et al., Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies, CLIN CANC R, 5(10), 1999, pp. 3304S-3314S
Authors:
Beyer-Sehlmeyer, G
Hiddemann, W
Wormann, B
Bertram, J
Citation: G. Beyer-sehlmeyer et al., Suppressive subtractive hybridisation reveals differential expression of serglycin, sorcin, bone marrow proteoglycan and prostate-tumour-inducing gene I (PTI-1) in drug-resistant and sensitive tumour cell lines of haematopoetic origin, EUR J CANC, 35(12), 1999, pp. 1735-1742
Authors:
Feuring-Buske, M
Haase, D
Buske, C
Hiddemann, W
Wormann, B
Citation: M. Feuring-buske et al., Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission, LEUKEMIA, 13(3), 1999, pp. 386-392
Authors:
Hiddemann, W
Kern, W
Schoch, C
Fonatsch, C
Heinecke, A
Wormann, B
Buchner, T
Citation: W. Hiddemann et al., Management of acute myeloid leukemia in elderly patients, J CL ONCOL, 17(11), 1999, pp. 3569-3576
Authors:
Peters, AMJ
Kohfink, B
Martin, H
Griesinger, F
Wormann, B
Gahr, M
Roesler, J
Citation: Amj. Peters et al., Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, andHodgkin's disease, EXP HEMATOL, 27(5), 1999, pp. 868-874
Authors:
Behr, TM
Memtsoudis, S
Vougioukas, V
Liersch, T
Gratz, S
Schmidt, F
Lorf, T
Post, S
Wormann, B
Hiddemann, W
Ringe, B
Becker, W
Citation: Tm. Behr et al., Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: Preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial, ANTICANC R, 19(4A), 1999, pp. 2427-2432
Authors:
Verbeek, W
Wormann, B
Koch, P
Aul, C
Hinrichs, HF
Balleisen, L
Rowe, JM
Bennett, J
Haase, D
Fonatsch, C
Heinecke, A
Buchner, T
Hiddemann, W
Citation: W. Verbeek et al., Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes, J CANC RES, 125(6), 1999, pp. 369-374
Authors:
Humpe, A
Riggert, J
Munzel, U
Repas-Humpe, LM
Vehmeyer, K
Brunner, E
Wormann, B
Kohler, M
Citation: A. Humpe et al., A prospective, randomized, sequential, crossover trial of large-volume versus normal-volume leukapheresis procedures: effect on progenitor cells and engraftment, TRANSFUSION, 39(10), 1999, pp. 1120-1127